Glycine is an inhibitory neurotransmitter in the spinal cord and brain stem, where it activates strychninesensitive glycine receptors. It can also act as an excitatory neurotransmitter throughout the brain and spinal cord, where it is a co-agonist with glutamate at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Tw o subtypes of glycine transporters, GLYT1 and GLYT2, are used to regulate extracellular glycine concentrations and have the potential to modulate the dynamics of both inhibitory glycinergic and excitatory glutamatergic neurotransmission (Eulenburg et al.,2 005). GLYT1 is expressed in glial cells surrounding both excitatory and inhibitory synapses, whereas GLYT2 is expressed in presynaptic inhibitory glycinergic neurons (Kim et al.,1 994). Characterization of the different physiological roles of the twoG lyT subtypes has opened the possibility of pharmacologically manipulating glycine concentrations as potential means to treat schizophrenia (GLYT1 inhibitors) (Atkinson et al.,2 001; Aubrey&V andenberg, 2001) and pain (GLYT2 inhibitors) (Connor et al.,2010; Sur & Kinney, 2004; Vuong et al.,2008).
